Nicholas Richardson, DO, at Precision for Medicine, breaks down minimal residual disease and MRD negativity as FDA end points for faster myeloma approvals. Under this framework, MRD negativity is ...

Mitochondria possess their own mRNA translation system, mediated by specialized mitoribosomes. Dysregulation of mitochondrial translation disrupts metabolic homeostasis and is linked to various ...

FDA proposes MRD-negative and complete response endpoints to fast-track multiple myeloma drug approvals, pushing deeper molecular results over ORR.

The growth of the genomics market is driven by the rising prevalence of genetic disorders and cancer, along with increasing awareness of early disease detection through genetic testing. WILMINGTON, ...

STEMart announces the expansion of its genetic toxicology capabilities with the In Vivo Rat Micronucleus Test services.

A recent review concluded that artificial intelligence (AI) is rapidly transforming the diagnosis and treatment of haematological malignancies by enhancing diagnostic accuracy and ...

FDA has accepted the NDA for BMS's Iberdomide, an oral agent targetting relapsed/refractory multiple myeloma.

Iberdomide has the potential to be the first approved CELMoD agentThe U.S. FDA has granted Breakthrough Therapy Designation and Priority Review for this indication and assigned a target action date of ...

An fresh look at trial results that propelled the only FDA approval of a chimeric antigen receptor (CAR) T-cell therapy for mantle cell lymphoma (MCL) shows prior treatment with ibrutinib, a ...

Nonresponse to bridging therapy and high lymphocyte count were predictive of parkinsonism and nonrelapse mortality (NRM) after treatment with ciltacabtagene autoleucel (cilta-cel; Carvykti) in ...

The successful clinical validation of AlloHeme represents a key milestone in CareDx's Transplant+ strategy, expanding the Company's precision medicine capabilities into cell therapy, hematology, and ...